Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ErbB Receptors | 6 | 2014 | 513 | 1.630 |
Why?
|
| src Homology Domains | 6 | 2017 | 45 | 1.530 |
Why?
|
| Protein Array Analysis | 6 | 2017 | 52 | 0.970 |
Why?
|
| Proteins | 4 | 2017 | 816 | 0.950 |
Why?
|
| Protein Interaction Mapping | 3 | 2017 | 81 | 0.890 |
Why?
|
| Signal Transduction | 8 | 2015 | 3581 | 0.810 |
Why?
|
| Blotting, Western | 2 | 2017 | 796 | 0.740 |
Why?
|
| Proteome | 4 | 2015 | 156 | 0.730 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 91 | 0.500 |
Why?
|
| Fluorescence Polarization | 2 | 2014 | 12 | 0.490 |
Why?
|
| Quantitative Trait Loci | 3 | 2014 | 632 | 0.470 |
Why?
|
| Proteomics | 3 | 2017 | 268 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 80 | 0.420 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 120 | 0.400 |
Why?
|
| Phenylethyl Alcohol | 1 | 2012 | 1 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 200 | 0.380 |
Why?
|
| Caffeic Acids | 1 | 2012 | 5 | 0.370 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 21 | 0.370 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 46 | 0.370 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 206 | 0.330 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 280 | 0.330 |
Why?
|
| Phosphorylation | 5 | 2014 | 1157 | 0.310 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2090 | 0.300 |
Why?
|
| Cell Proliferation | 3 | 2012 | 1753 | 0.300 |
Why?
|
| Carcinoma | 1 | 2012 | 448 | 0.290 |
Why?
|
| Transcription Factors | 3 | 2014 | 1730 | 0.270 |
Why?
|
| Protein Binding | 5 | 2014 | 1560 | 0.220 |
Why?
|
| Cell Line, Tumor | 6 | 2017 | 2778 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1798 | 0.170 |
Why?
|
| Phosphotyrosine | 2 | 2014 | 31 | 0.170 |
Why?
|
| Systems Biology | 2 | 2011 | 47 | 0.160 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 2 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 74 | 0.160 |
Why?
|
| Phosphopeptides | 2 | 2012 | 11 | 0.160 |
Why?
|
| Surface Plasmon Resonance | 2 | 2012 | 48 | 0.150 |
Why?
|
| Rhodopseudomonas | 2 | 1989 | 51 | 0.150 |
Why?
|
| Nitrogen Fixation | 2 | 1989 | 37 | 0.150 |
Why?
|
| Genetic Variation | 3 | 2014 | 1423 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 188 | 0.140 |
Why?
|
| Genes, Bacterial | 2 | 1989 | 199 | 0.140 |
Why?
|
| Cisplatin | 2 | 2017 | 611 | 0.140 |
Why?
|
| Genome-Wide Association Study | 3 | 2014 | 1765 | 0.130 |
Why?
|
| Humans | 16 | 2020 | 96105 | 0.130 |
Why?
|
| Cell Line | 2 | 2014 | 2537 | 0.120 |
Why?
|
| Base Sequence | 4 | 2014 | 2344 | 0.110 |
Why?
|
| Computational Biology | 2 | 2011 | 586 | 0.110 |
Why?
|
| Genome, Human | 3 | 2014 | 824 | 0.110 |
Why?
|
| Amino Acid Sequence | 5 | 2010 | 2090 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 3157 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2015 | 263 | 0.100 |
Why?
|
| Tyrosine | 1 | 2014 | 132 | 0.100 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 101 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 270 | 0.100 |
Why?
|
| Animals | 9 | 2017 | 28891 | 0.100 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 1083 | 0.100 |
Why?
|
| Mice, Nude | 2 | 2012 | 830 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 385 | 0.100 |
Why?
|
| Genotype | 2 | 2014 | 1881 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 307 | 0.100 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 104 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 563 | 0.090 |
Why?
|
| Antibodies | 1 | 2014 | 356 | 0.090 |
Why?
|
| Cytotoxins | 1 | 2012 | 17 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 307 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2014 | 456 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 553 | 0.090 |
Why?
|
| Transcriptome | 2 | 2014 | 769 | 0.090 |
Why?
|
| Cell Physiological Phenomena | 1 | 2011 | 27 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2014 | 984 | 0.090 |
Why?
|
| Binding Sites | 1 | 2014 | 1167 | 0.090 |
Why?
|
| Viruses | 1 | 2011 | 75 | 0.090 |
Why?
|
| DNA, Bacterial | 2 | 1989 | 253 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 910 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 2061 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2012 | 526 | 0.080 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2010 | 2 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 528 | 0.080 |
Why?
|
| HIV Infections | 1 | 2020 | 974 | 0.080 |
Why?
|
| Gene Expression | 1 | 2014 | 1320 | 0.080 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 20 | 0.080 |
Why?
|
| Sirolimus | 1 | 2011 | 177 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 91 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 1124 | 0.080 |
Why?
|
| Methionine | 1 | 2009 | 68 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 2418 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1535 | 0.080 |
Why?
|
| Indoles | 1 | 2011 | 317 | 0.070 |
Why?
|
| Equipment Design | 1 | 2010 | 427 | 0.070 |
Why?
|
| Receptor, ErbB-4 | 1 | 2008 | 5 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1267 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2011 | 541 | 0.070 |
Why?
|
| Software | 2 | 2015 | 698 | 0.060 |
Why?
|
| Algorithms | 1 | 2015 | 2015 | 0.060 |
Why?
|
| Peptides | 1 | 2010 | 671 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2009 | 473 | 0.060 |
Why?
|
| Breast | 1 | 2008 | 297 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 464 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2494 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 3040 | 0.060 |
Why?
|
| Mice | 4 | 2012 | 12537 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2039 | 0.060 |
Why?
|
| Heart | 1 | 2008 | 591 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2005 | 477 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 1105 | 0.050 |
Why?
|
| Magnesium Chloride | 1 | 2004 | 6 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2017 | 317 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1089 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 750 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1429 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2880 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 86 | 0.050 |
Why?
|
| Prognosis | 1 | 2008 | 4028 | 0.040 |
Why?
|
| Genomics | 1 | 2005 | 857 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 1670 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 164 | 0.040 |
Why?
|
| Tribolium | 1 | 1997 | 10 | 0.030 |
Why?
|
| Brain | 1 | 2008 | 2482 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 199 | 0.030 |
Why?
|
| Hybridization, Genetic | 1 | 1997 | 107 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 810 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 488 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 2578 | 0.030 |
Why?
|
| Apoptosis | 2 | 2014 | 1756 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 667 | 0.030 |
Why?
|
| Male | 3 | 2020 | 45863 | 0.030 |
Why?
|
| Drug Design | 1 | 2015 | 133 | 0.030 |
Why?
|
| HapMap Project | 1 | 2014 | 47 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2014 | 497 | 0.020 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Interferons | 1 | 2011 | 130 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 124 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2010 | 28 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 114 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 411 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 98 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 206 | 0.020 |
Why?
|
| RNA, Transfer, Met | 1 | 2009 | 6 | 0.020 |
Why?
|
| Genetic Code | 1 | 2009 | 26 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 360 | 0.020 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 48 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 217 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2010 | 422 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1049 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2009 | 85 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 393 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 354 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 368 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 1030 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2009 | 342 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 522 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 478 | 0.020 |
Why?
|
| Female | 4 | 2020 | 50028 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1987 | 45 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 517 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 611 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1375 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3489 | 0.010 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2004 | 10 | 0.010 |
Why?
|
| Culture Media | 1 | 2004 | 150 | 0.010 |
Why?
|
| Heparin | 1 | 2004 | 186 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 564 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2004 | 627 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 28368 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 28721 | 0.010 |
Why?
|
| Sexual Behavior, Animal | 1 | 1997 | 95 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1809 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1987 | 175 | 0.000 |
Why?
|
| Species Specificity | 1 | 1987 | 707 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1987 | 463 | 0.000 |
Why?
|
| DNA | 1 | 1987 | 1333 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 4155 | 0.000 |
Why?
|